Adial Pharmaceuticals Files 8-K Amendment Adding Pro Forma Merger Financials

What Happened Adial Pharmaceuticals, Inc. (ADIL) filed an amendment to its original Form 8-K on August 11, 2026 (Item 9.01) to provide the required financial information omitted from the original filing. The amendment attaches unaudited pro forma condensed combined financial information and related notes as Exhibit 99.3 and states that the amendment should be read together with the Original Form 8-K.

Key Details

• Filing type: Amendment to Form 8-K (Item 9.01) filed August 11, 2026.
• Exhibit added: Exhibit 99.3 — unaudited pro forma condensed combined financial information and related notes.
• Purpose: The pro forma information is provided for informational purposes only and does not represent actual historical results or any forecasted future financial position or results of operations.
• Scope: No other updates were made to the Original Form 8-K; the company did not update other information to reflect events after the Original Form 8-K.

Why It Matters The amendment supplies investors with the pro forma financials tied to Adial’s previously disclosed merger, offering a view of how the combined companies might have appeared financially on a pro forma basis. However, because the figures are unaudited and expressly not predictive of future results, investors should treat them as supplementary information for context rather than as definitive evidence of future performance.